SEBI, when can Indian markets see SPACs?

After almost 30 years of moving towards a capitalistic market model, India still has a long way to go. Efficient allocation of capital, risk taking, animal spirits: we don’t truly get this. Banking system is stuck in NPA mess, which the bankruptcy law IBC has not been able to make…

Read More

Should India withdraw from Asian Infrastructure Investment Bank?

The Asian Infrastructure Investment Bank (AIIB) is a new multi-lateral lending institution that came about in Jan 2016. AIIB is a Chinese baby. It was proposed by China; it is headquartered in Beijing. A Chinese, Jin Liqun, is the current President of AIIB. Below him, there are 5 vice presidents,…

Read More

Reliance Industries as a Private Equity LP

Ever since its early years, Reliance Industries Limited (RIL), India’s largest private sector enterprise, has believed in running an active treasury. Beyond supporting business requirements, RIL’s treasury has often taken investment positions, in areas like listed equity. In the ‘80s and ‘90s, it was a fairly commonplace practice amongst listed…

Read More

China’s monthly biotech investments headed towards USD1B+ consistently

Earlier this week we wrote how on 2 consecutive months, China’s biotech sector had witnessed more than USD1B of venture capital investment. That chart ignored another source of risk capital – IPOs. China has been producing around 1 biotech IPO a month consistently. These are typically pre-revenue R&D companies, but…

Read More

China’s supercharged biotech investment momentum continues in May’20

For the second month in a row, China’s biotech companies attracted more than USD1B of venture capital investment. Biotech investments crossed USD1B for the first time in April’20. Hence, May is the second consecutive month where VC/PE investments in biotech have crossed USD1B. In terms of amout invested, China inching…

Read More